2023
Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy
Desai S, Sumransub N, Evans R, Watkins M, Karmali R, Goyal G, Hughes M, Khurana A, Hernandez-Ilizaliturri F, Zurko J, Hassan A, Hatic H, Nizamuddin I, Evens A, Anampa-Guzmán A, Lin Y, Isufi I, Hamadani M, Rajguru S, Lall N, Tun A, Hill B, Stephens D, Caimi P, Ermann D, Kahl B, Landsburg D, Nowakowski G. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy. Blood 2023, 142: 308. DOI: 10.1182/blood-2023-183001.Peer-Reviewed Original ResearchHigh-grade B-cell lymphomaCART-cell therapyProgression-free survivalOverall survivalInferior overall survivalB-cell lymphomaCART cellsCell therapyRetrospective studyEra cohortCell lymphomaBCL6 rearrangementsLarge B-cell lymphomaAnthracycline-based therapySuperior overall survivalMulticenter retrospective studyHigher overall survivalElectronic health recordsAdult ptsPrior chemotherapyYr OSB symptomsBulky diseaseCART eraElevated LDH
2015
The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.Peer-Reviewed Original ResearchConceptsGastrointestinal acute GVHDAcute GVHDGrade IIIAllogeneic stem cell transplantCombination of basiliximabSevere GI GvHDSevere grade IIISteroid-refractory diseaseLong-term survivorsStem cell transplantOverall response rateCurrent retrospective studyChronic GVHDGI GVHDSalvage therapySteroid therapyPrimary diseaseCell transplantMedian timeSignificant morbidityPoor outcomeRetrospective studyGVHDMost deathsNew agents